Ipca Laboratories

Mumbai, India Founded: 1949 • Age: 77 yrs Listed Fortune India 500 · #286
APIs and drug formulations are manufactured for therapeutic segments.
Request Access
Report Incorrect Data
Page last updated

About Ipca Laboratories

Ipca Laboratories is a publicly listed company based in Mumbai (India) founded in 1949. APIs and drug formulations are manufactured for therapeutic segments. It operates on a Reseller / Distribution model. The company has 23,240 employees. Ipca Laboratories has completed 3 acquisitions, including Bayshore Pharmaceuticals, Noble Explochem and Ramdev Chemicals. Its chief executive, as recorded, is Pranay Godha. Its website ipca.com draws about 21 thousand monthly visits. Its Indian entity Ipca Laboratories Limited reported revenue of ₹9,838 Cr. Ipca Laboratories offers products and services including APIs, Formulations, and Generics. Its focus areas include Pharmaceuticals and Generic Drugs.

Company details

Ipca Laboratories is involved in the production and distribution of active pharmaceutical ingredients (APIs), formulations, and generic medicines. The company operates within the healthcare sector, focusing on providing affordable healthcare solutions globally. Emphasis is placed on backward integration to ensure a reliable supply chain and cost competitiveness. Expansion in the generic drug space is pursued to enhance market reach. Corporate social responsibility initiatives are undertaken to support patient health, environmental sustainability, and community development.

Ipca Laboratories is ranked #286 on the Fortune India 500 (2025).

Recognitions & Rankings of Ipca Laboratories

Fortune India 500 2025 edition
Rank#286
Total income
₹9,078 Cr
Profit
₹738 Cr
Last year #292
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#163
Valuation
₹38,670 Cr
2023 #173 2022 #178 2021 #150
  • Headquarters Mumbai, India
  • Employees 23,240
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Phone
    •••• ••••
  • Website ipca.com
  • Social LinkedIn Facebook
  • Legal Name Ipca Laboratories Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹48,869 Cr

    IPCALAB · NSE

  • Share Price
    ₹1,927.80

    +0.08% today

  • Revenue
    ₹9,646 Cr

    FY 2025-26 · +7.9% YoY

  • EBITDA
    ₹1,878 Cr

    Margin 19.5%

  • Net Profit
    ₹1,180 Cr

    FY 2025-26 · +38.2% YoY

  • P/E (TTM)
    35.7x

    P/B 6.1x

  • ROE
    15.9%

    ROCE 19.0%

  • Debt / Equity
    0.14

    Interest cover 5.4x

  • Latest Funding Round
    $40M (USD), Post-IPO

    Mar 2013

  • Investors
    ChrysCapital
  • Employee Count
    23,240
  • Investments & Acquisitions
    Bayshore Pharmaceuticals

    & 2 more

Products & Services of Ipca Laboratories

Ipca Laboratories offers a comprehensive portfolio of products and services, including APIs, Formulations, and Generics.

APIs
Pharmaceuticals

Active pharmaceutical ingredients are produced for global markets.

Formulations
Pharmaceuticals

Formulated drugs are developed for various health conditions.

Generics
Pharmaceuticals

Generic medicines are offered at competitive market prices.

Funding Insights of Ipca Laboratories

  • Total Rounds 1
  • Last Round Post-IPO — $40M
  • First Round $40M

    (Mar 2013)

  • Investors Count 1

All 1 funding rounds of Ipca Laboratories with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2013$40MPost-IPO––
ChrysCapital
Valuation history

1 investors in total: 1 institutional.

Investors in Ipca Laboratories

Ipca Laboratories has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include ChrysCapital.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
ChrysCapital
Investment firm focusing on private equity in sectors like financial services and healthcare.
1999chryscapital.com
Premium access

Investor details for Ipca Laboratories

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Ipca Laboratories Limited (Ipca Laboratories)

Ipca Laboratories Limited is the primary company behind Ipca Laboratories. The board of Ipca Laboratories Limited currently have 8 directors; the longest-serving is Pranay Premchand Godha, appointed in 2009. 11 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Pranay Premchand Godha
DIN 00016525
Managing Director30 Jul 200917 yrs 3 moIpca Laboratories Limited
Ajit Kumar Jain
DIN 00012657
Managing Director21 Aug 200917 yrs 2 moIpca Laboratories Limited
Prashant Godha
DIN 00012759
Director28 Jul 201115 yrs 3 moIpca Laboratories Limited
Premchand Gigalal Godha
DIN 00012691
Whole-time director31 Jan 201214 yrs 9 moIpca Laboratories Limited
Kamal Kishore Seth
DIN 00194986
Director29 Mar 20197 yrs 7 moIpca Laboratories Limited
Narendra Mairpady
DIN 00536905
Director20 Oct 20224 yrsIpca Laboratories Limited
Swati Arvind Patankar
DIN 06594600
Director14 Feb 20242 yrs 8 moIpca Laboratories Limited
Vivek Keshav Shiralkar
DIN 00340316
Director29 May 20242 yrs 5 moIpca Laboratories Limited

People of Ipca Laboratories

45 people are tracked at Ipca Laboratories (23 in leadership, 4 in board & advisors, 18 in team); the tracked headcount is 23,240.

NameRoleGroup
Ajit Kumar Jain
Managing DirectorLeadership
Pranay Godha
CEO & Managing DirectorLeadership
Premchand Godha
Chairman & Managing DirectorLeadership
Ashok Kumar
President, R&D (Chemical)Leadership
Kavita Sehwani
President, GenericsLeadership
Prabodh Dwivedi
Head Of Quality AssuranceLeadership
Rajendra Dadhich
Senior Vice President - Corporate QualityLeadership
Anil Pareek
President, Medical Affairs & Clinical ResearchLeadership
Shailesh Laul
President, Operations (Formulations)Leadership
Goutam Muhuri
President, R&D (Formulations)Leadership
Dr. Janardhana Rao Vascuri
Associate Vice President - Head R&d (api)Leadership
Dr Indranil Purkait
Sr General ManagerLeadership
Srikant Pande
Site Head ( Formulation) General ManagerLeadership
Shashi Kant
Manager, QC Head At IPCA Laboratory Ltd.Leadership
Nitin Chandurkar
Senior Vice President Global Clinical Research And DevelopmentLeadership
Dr. Ghanshyam Maurya
Assistant General Manager API R&dLeadership
Yogendra Singh Bisht Bisht
Assistant General ManagerLeadership
Dr.ashvini Saxena
Vice President R&dLeadership
Harvinder Singh
Associate Vice President - Analytical Development At Ipca Laboratories LimitedLeadership
Krishna Kumar
Deputy General ManagerLeadership

25 more people are available in the full profile.

Premium access

Complete people profiles for Ipca Laboratories

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Ipca Laboratories

Ipca Laboratories is a publicly listed company on the NSE with ticker symbol IPCALAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date08 Feb 1995
  • Listed onNSE: IPCALAB
  • Listed entityIPCA Laboratories Limited
  • Exchange sectorHealth technology
  • ISININE571A01038
  • Share price₹1,911.60 (-0.4% on the day) · 2026-10-14
  • Market capitalisation₹48,713 Cr
  • Price to earnings37.0
  • EPS (diluted, trailing year)₹51.63
  • Dividend yield0.31%
  • Volume (last session)205,495

Financials of Ipca Laboratories

Exchange-reported figures of Ipca Laboratories Limited, the listed company behind Ipca Laboratories (NSE: IPCALAB).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹9,646 Cr
+7.9% YoY
EBITDA
₹1,878 Cr
+23.2% YoY
Profit After Tax
₹1,180 Cr
+38.2% YoY
Net Worth
₹8,064 Cr
+16.1% YoY
Total Assets
₹10,431 Cr
+5.9% YoY
Total Debt
₹809 Cr
-40.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,6468,9407,7056,2445,8305,4204,619
Revenue growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%-
EBITDA1,8781,5241,1489291,3131,548902
EBITDA margin+19.5%+17.1%+14.9%+14.9%+22.5%+28.6%+19.5%
Profit before tax1,5731,1318437451,1361,389739
Net profit1,1808545944548851,134597
Net profit margin+12.2%+9.6%+7.7%+7.3%+15.2%+20.9%+12.9%
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
Balance sheet
Total assets10,4319,8489,2537,4446,4215,0224,176
Net worth8,0646,9486,3325,8425,4924,7023,627
Total debt8091,3631,4381,481807265501
Cash & bank5653442971,853641365181
Net working capital4,0463,5863,4403,8732,6622,1311,676
Cash flow
Cash from operations1,1421,3219458068561,090570
Cash from investing(247)(870)(1,215)(725)(851)(521)(509)
Cash from financing(754)(283)(553)507427(306)(137)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,7882,3882,3922,5562,3092,2472,2452,355
Revenue growth (YoY)+20.8%+6.3%+6.6%+8.6%+10.3%---
Other income25.2693.7437.8427.8632.6625.8220.1126.26
EBITDA670438533487416224463441
EBITDA margin+24.0%+18.3%+22.3%+19.0%+18.0%+10.0%+20.6%+18.7%
Depreciation11110710810310010098.46100
Interest11.8820.2017.6219.6118.5121.5116.8122.56
Profit before tax572404446392331128368345
Tax14995.0581.9310896.0962.2290.5999.39
Net profit42330936428423465.78277245
EPS (₹)15.8411.7912.8611.149.192.679.789.05
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue7,3376,6786,1665,8155,4385,1394,338
Revenue growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%-
EBITDA1,7521,2461,0809141,2411,517918
EBITDA margin+23.9%+18.7%+17.5%+15.7%+22.8%+29.5%+21.2%
Profit before tax1,5321,0008227501,0741,380785
Net profit1,1368206004888531,132642
Net profit margin+15.5%+12.3%+9.7%+8.4%+15.7%+22.0%+14.8%
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
Balance sheet
Total assets8,3437,8567,5517,3656,2965,0284,185
Net worth7,9796,8926,3495,8775,4764,7533,678
Total debt2959061,1521,440776236474
Cash & bank3631651131,706596307152
Net working capital2,4032,1042,1743,6492,5222,0371,615
Cash flow
Cash from operations1,3781,3748317628321,096561
Cash from investing(697)(739)(1,355)(710)(812)(560)(499)
Cash from financing(745)(428)(465)506426(307)(139)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,1191,8141,8451,9301,7471,6381,6631,811
Revenue growth (YoY)+21.3%+10.7%+11.0%+6.6%+11.6%---
Other income17.4229.8817.8221.9225.0221.4917.4117.00
Total expenses1,5421,4141,3681,4661,3401,5611,2521,409
EBITDA57840147746540777.05411402
EBITDA margin+27.3%+22.1%+25.9%+24.1%+23.3%+4.7%+24.7%+22.2%
Depreciation74.6170.3168.5766.8663.1365.1962.8162.65
Interest5.0410.489.5111.4612.0616.2010.1717.25
Profit before tax51535041740835717.15356339
Tax14287.5611410494.7182.2087.9695.09

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,7882,3882,3922,5562,3092,2472,2452,355
Revenue growth (YoY)+20.8%+6.3%+6.6%+8.6%+10.3%---
Other income25.2693.7437.8427.8632.6625.8220.1126.26
EBITDA670438533487416224463441
EBITDA margin+24.0%+18.3%+22.3%+19.0%+18.0%+10.0%+20.6%+18.7%
Depreciation11110710810310010098.46100
Interest11.8820.2017.6219.6118.5121.5116.8122.56
Profit before tax572404446392331128368345
Tax14995.0581.9310896.0962.2290.5999.39
Net profit42330936428423465.78277245
EPS (₹)15.8411.7912.8611.149.192.679.789.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,6468,9407,7056,2445,8305,4204,619
Revenue growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%-
Other income19292.8019312666.5762.8467.00
Total expenses7,7697,4166,5575,3154,5173,8723,717
Employee cost2,1601,9841,7081,2881,1771,014921
EBITDA1,8781,5241,1489291,3131,548902
EBITDA margin+19.5%+17.1%+14.9%+14.9%+22.5%+28.6%+19.5%
Depreciation418398357262232209210
Interest79.0987.8414148.1911.2012.2719.77
Profit before tax1,5731,1318437451,1361,389739
Tax381344313253225240135
Net profit1,1808545944548851,134597
Net profit margin+12.2%+9.6%+7.7%+7.3%+15.2%+20.9%+12.9%
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.3725.3725.3725.3725.3725.3725.27
Reserves & surplus8,0386,9236,3075,8175,4674,6763,590
Shareholders' funds (net worth)8,0646,9486,3325,8425,4924,7023,627
Minority interest1,4601,4401,39573.3076.9214.5313.63
Secured loans7041,1561,210858555141324
Unsecured loans105206229623253124176
Total debt8091,3631,4381,481807265501
Total liabilities10,4319,8489,2537,4446,4215,0224,176
Assets
Gross block7,6926,9957,0214,3653,7593,2122,986
Net block4,6274,2674,5542,7512,4182,0722,059
Capital work in progress773622343140306235133
Investments844980862626989505310
Inventories2,7312,5602,4711,7431,8581,5951,323
Sundry debtors2,0141,8841,687989911812895
Cash & bank balances5653442971,853641365181
Loans & advances430415522280318272218
Total current assets5,7405,2044,9774,8663,7273,0432,617
Total current liabilities1,6941,6181,5389931,065913942
Net working capital4,0463,5863,4403,8732,6622,1311,676
Total assets10,4319,8489,2537,4446,4215,0224,176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash9257561,579991559295371
Net cash from operating activities1,1421,3219458068561,090570
Net cash from investing activities(247)(870)(1,215)(725)(851)(521)(509)
Net cash from financing activities(754)(283)(553)507427(306)(137)
Net change in cash142169(823)588432264(75.53)
Closing cash5653442971,853641365181
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%-
EBITDA growth+23.2%+32.8%+23.5%-29.2%-15.2%+71.5%-
PBT growth+39.0%+34.2%+13.1%-34.4%-18.2%+88.0%+35.2%
Net income growth+38.2%+43.8%+30.7%-48.7%-21.9%+90.0%-
Revenue CAGR (3Y)+15.6%+15.3%+12.4%+10.6%+15.9%+18.5%+13.5%
EBITDA CAGR (3Y)+26.4%+5.1%-9.5%+1.0%+23.7%+50.5%+26.2%
Profitability & leverage
Net income margin+12.4%+8.8%+6.9%+7.9%+15.6%+21.2%+13.1%
Return on capital employed+19.0%+17.1%+12.9%+11.6%+20.2%+30.6%+19.5%
Return on net worth+15.9%+13.6%+8.7%+8.7%+17.9%+27.6%+17.9%
Debt / equity0.140.210.240.200.110.090.14
Long-term debt / equity0.050.090.110.100.040.020.04
Interest cover5.427.8017.807.221.040.922.86
Efficiency & per share
Fixed asset turnover1.311.281.351.541.671.751.65
Inventory turnover3.653.553.663.473.383.713.88
Debtors turnover4.955.015.766.576.776.355.90
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
Dividend per share (₹)0.004.004.004.008.008.005.00
Book value per share (₹)317.85273.88249.59230.27216.47370.65286.15
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,1191,8141,8451,9301,7471,6381,6631,811
Revenue growth (YoY)+21.3%+10.7%+11.0%+6.6%+11.6%---
Other income17.4229.8817.8221.9225.0221.4917.4117.00
Total expenses1,5421,4141,3681,4661,3401,5611,2521,409
EBITDA57840147746540777.05411402
EBITDA margin+27.3%+22.1%+25.9%+24.1%+23.3%+4.7%+24.7%+22.2%
Depreciation74.6170.3168.5766.8663.1365.1962.8162.65
Interest5.0410.489.5111.4612.0616.2010.1717.25
Profit before tax51535041740835717.15356339
Tax14287.5611410494.7182.2087.9695.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue7,3376,6786,1665,8155,4385,1394,338
Revenue growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%-
Other income94.6471.2911111152.9262.2464.69
Total expenses5,5855,4325,0874,9004,1973,6233,420
Employee cost1,6561,4791,3361,1931,102949871
EBITDA1,7521,2461,0809141,2411,517918
EBITDA margin+23.9%+18.7%+17.5%+15.7%+22.8%+29.5%+21.2%
Depreciation269252246229210188179
Interest45.4665.0612346.3410.4111.1318.84
Profit before tax1,5321,0008227501,0741,380785
Tax400349292245214239133
Net profit1,1368206004888531,132642
Net profit margin+15.5%+12.3%+9.7%+8.4%+15.7%+22.0%+14.8%
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.3725.3725.3725.3725.3725.3725.27
Reserves & surplus7,9546,8666,3235,8525,4504,7273,640
Shareholders' funds (net worth)7,9796,8926,3495,8775,4764,7533,678
Secured loans235726991858555114298
Unsecured loans60.06180161582222123176
Total debt2959061,1521,440776236474
Total liabilities8,3437,8567,5517,3656,2965,0284,185
Assets
Gross block5,0374,3884,1663,8893,3652,8992,689
Net block2,9692,5372,5242,4792,1531,8691,841
Capital work in progress45949017512329718284.19
Investments2,5362,6932,6541,0571,339868649
Inventories1,7081,5421,6771,6601,7801,5171,267
Sundry debtors1,2721,1661,027926824774839
Cash & bank balances3631651131,706596307152
Loans & advances304255282260306285215
Total current assets3,6473,1283,0994,5523,5052,8842,474
Total current liabilities1,2441,024925903983847859
Net working capital2,4032,1042,1743,6492,5222,0371,615
Total assets8,3437,8567,5517,3656,2965,0284,185
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash7225151,505946500272348
Net cash from operating activities1,3781,3748317628321,096561
Net cash from investing activities(697)(739)(1,355)(710)(812)(560)(499)
Net cash from financing activities(745)(428)(465)506426(307)(139)
Net change in cash(64.08)207(990)559446229(76.37)
Closing cash3631651131,706596307152
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%-
EBITDA growth+40.7%+15.3%+18.1%-26.3%-18.2%+65.2%-
PBT growth+53.3%+21.6%+9.6%-30.1%-22.2%+75.8%+40.8%
Net income growth+38.5%+36.7%+22.9%-42.7%-24.7%+76.5%-
Revenue CAGR (3Y)+8.1%+7.1%+6.3%+10.3%+14.7%+17.2%+11.8%
EBITDA CAGR (3Y)+24.2%+0.1%-10.7%-0.1%+21.3%+50.5%+28.3%
Profitability & leverage
Net income margin+15.4%+9.7%+8.6%+8.7%+15.8%+22.2%+15.0%
Return on capital employed+19.5%+17.2%+14.1%+11.7%+19.2%+30.2%+20.6%
Return on net worth+15.2%+12.4%+9.8%+8.9%+16.8%+27.1%+19.2%
Debt / equity0.080.160.210.200.100.080.13
Long-term debt / equity0.040.080.100.090.040.010.03
Interest cover3.076.5514.716.761.010.842.55
Efficiency & per share
Fixed asset turnover1.561.561.531.601.741.841.71
Inventory turnover4.524.153.703.383.303.693.76
Debtors turnover6.026.096.316.646.806.375.94
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
Dividend per share (₹)6.004.004.004.004.008.005.00
Book value per share (₹)314.52271.64250.24231.66215.84374.67290.11

Investments & Acquisitions by Ipca Laboratories

Ipca Laboratories has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Bayshore Pharmaceuticals, Noble Explochem and Ramdev Chemicals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Noble Explochem
Industrial chemicals and explosives are manufactured and distributed.
noble-explochem.comNagpur, India0Jan 2020$9.69M
Ramdev Chemicals
APIs, intermediates, specialty chemicals, and custom synthesis molecules are manufactured.
ramdevchem.comMumbai, India1999Apr 2019$15.53M
Bayshore Pharmaceuticals
Manufacturer of pharmaceutical products
bayshoreus.comShort Hills, United States2011Oct 2018$10.29M
Premium access

Complete acquisition details for Ipca Laboratories

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Ipca Laboratories

6 dated milestones of Ipca Laboratories across 71 years, from founding to its latest funding, stage changes and deals.

  1. Founded Ipca Laboratories is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $40.0M.
  4. Acquisition Acquires Bayshore Pharmaceuticals.
  5. Acquisition Acquires Ramdev Chemicals.
  6. Acquisition Acquires Noble Explochem.

Web traffic of Ipca Laboratories

The website of Ipca Laboratories (ipca.com) receives about 20.7K visits a month and ranks #1,302,903 among all websites worldwide, #1,673 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    20.7K

    ▲ 12.3% vs previous month

  • Unique visitors
    8.1K

    per month

  • Global rank
    #1,302,903

    among all websites

  • Category rank
    #1,673

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Ipca Laboratories. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Ipca Laboratories
ipcalabs.com
100%
#6,089,785View details
anmol.org
anmol.org
78%
#4,348,220–
Micro Labs
microlabsltd.com
74%
#1,920,866View details
USV India
usvindia.com
72%
11.4K#2,386,041View details
unisonlab.com
unisonlab.com
72%
–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 16 similar websites and full traffic analytics for Ipca Laboratories

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Ipca Laboratories (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ipca Laboratories

Technical analysis: Two Trades for Today: A mid-cap pharma stock for a 5.3% upmove, a capital goods manufacturer for an almost 7% gain - The Economic Times
Economic Times • 1 month ago
Momentum Stocks: PNB Housing Finance, Divis Labs, Ipca Labs, Paytm hit 52-week high
Moneycontrol • 2 months ago
Buy Ipca Laboratories; target of Rs 2060: Motilal Oswal
Moneycontrol • 2 months ago
Ipca Laboratories shares gain 5.35% to Rs 1,827
Moneycontrol • 2 months ago
Buy Ipca Laboratories; target of Rs 2000: Prabhudas Lilladher
Moneycontrol • 2 months ago
Buy Ipca Laboratories; target of Rs 1950: Emkay Global Financial
Moneycontrol • 2 months ago
Momentum Stocks: Ipca Labs, Expleo Solution, Armour Security advance amid sheer momentum
Moneycontrol • 2 months ago
Ipca Laboratories shares jump 12% to hit record high on strong Q1 show; check revised target prices - BusinessToday
Business Today • 2 months ago
IPCALAB: Revenue up 21% and EBITDA margin to 22.88%, with FY27 growth guidance raised to 14%-16%
Quartr • 2 months ago
Ipca Laboratories shares fall over 2%; strong financial performance reported
Moneycontrol • 2 months ago
Premium access

Complete news archive for Ipca Laboratories

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ipca Laboratories

Ipca Laboratories was founded in 1949 and raised its 1st funding round 64 years after it was founded.

Ipca Laboratories is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Pranay Godha is the CEO of Ipca Laboratories, as recorded in our data.

Ipca Laboratories has 23,240 employees.

The primary company behind Ipca Laboratories, Ipca Laboratories Limited, reported revenue of ₹9,838 Cr for FY 2026, up 8% year on year.

Ipca Laboratories is involved in the production and distribution of active pharmaceutical ingredients (APIs), formulations, and generic medicines. The company operates within the healthcare sector, focusing on providing affordable healthcare solutions globally. Emphasis is placed on backward integration to ensure a reliable supply chain and cost competitiveness. Expansion in the generic drug space is pursued to enhance market reach. Corporate social responsibility initiatives are undertaken to support patient health, environmental sustainability, and community development.

Ipca Laboratories offers APIs, Formulations, and Generics.

Yes, Ipca Laboratories is publicly traded on NSE under the ticker symbol IPCALAB.

Ipca Laboratories has made 3 acquisitions, including Bayshore Pharmaceuticals, Noble Explochem, and Ramdev Chemicals.

Ipca Laboratories has 1 investor. Key investors include ChrysCapital.

Ipca Laboratories operates through Ipca Laboratories Limited.

The legal entities of Ipca Laboratories currently have 9 directors, including Narendra Mairpady, Ajit Kumar Jain, Kamal Kishore Seth and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available